Raymond James Financial Inc Cytom X Therapeutics, Inc. Transaction History
Raymond James Financial Inc
- $280 Billion
- Q2 2025
A detailed history of Raymond James Financial Inc transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Raymond James Financial Inc holds 283,560 shares of CTMX stock, worth $952,761. This represents 0.0% of its overall portfolio holdings.
Number of Shares
283,560Holding current value
$952,761% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CTMX
# of Institutions
88Shares Held
123MCall Options Held
305KPut Options Held
121K-
Vr Adviser, LLC New York, NY14MShares$46.9 Million6.28% of portfolio
-
Tang Capital Management LLC San Diego, CA11.1MShares$37.2 Million1.5% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.38MShares$31.5 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA8.46MShares$28.4 Million0.69% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct8.08MShares$27.2 Million0.04% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $222M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...